Protamine, chitooligosaccharide reduce cholesterol levels
By David Liu PHD
Tuesday Oct 16, 2012 (foodconsumer.org) -- A new study in Molecular Medicine Reports suggests taking dietary supplements protamine or chitooligosaccharide (COS) or both decreased serum levels of triglycerides, total cholesterol, low density lipoprotein cholesterol and increased serum high density lipoprotein cholesterol.
N.H. Kang at Chungbuk National University in Cheongju, Chungbuk, Republic of Korea and colleagues conducted the study and found rats fed protamine and or chitooligosaccharide had lower cholesterol.
For the current study, the researchers examined lipid profiles and the potential effect of protamine and chitooligosaccharide on cardiovascular disease risk in male Sprague-DAWley rats.
Using protamine or chitooligosacharide or both significantly lowered anthrogenic index and cardiac risk factor and cardiovascular disease risk, which were associated with high concentrations of triglycerides, total cholesterol, low density lipoprotein cholesterol and low concentrations of high density lipoprotein cholesterol.
Accumulation of lipids in the liver of the rats fed high-fat diets was also inhibited by using protamine and COS.
The researchers concluded "Our findings suggest that protamine, COS and combinations of the two compounds may be used as a dietary therapy for preventing CVD due to their suppressive effects on hyperlipidemia and hypercholesterolemia."
Protamine is a novel dietary protein prepared from salmon spermaries and chitooligosaccharide is an oligosaccharide prepared from chitin or chitosan. These two compounds have already been known to enhance lipid metabolism.
(Send your news to email@example.com, Foodconsumer.org is part of the Infoplus.com ™ news and information network)
- What temperature to Cook a Turkey - Safe Cooking
- Senator Durbin to Reintroduce Supplement Bill
- The "Safe" Garden Product that Can Destroy Your DNA
- Addictive and Toxic: Found in Bread, Pasta Sauce and Salad Dressing
- Physical Exercise cuts dementia risk